Abstract Body

Adherence is critical to achieve the benefits of antiretroviral therapy (ART). Smart-pill bottles (AdhereTech) securely transmit real-time adherence information via cellular networks to a central service that sends prompts to non-adherent patients by phone call or text in addition to on-device visual and audio cues. The smart-pill bottle service may improve adherence to ART.

Adults with HIV taking a tenofovir disoproxil fumarate (TDF)-containing regimen with suboptimal adherence (2 detectable HIV RNA assays during the prior year) were randomized to receive adherence counseling with or without the smart-pill bottle service for 12 weeks. Tenofovir diphosphate (TFV-DP) levels by dried blood spot, HIV RNA, CD4 levels, and self-reported adherence (using the AIDS Clinical Trials Group [ACTG] Adherence Questionnaire) were collected.

63 participants (22% women; 48% black, 25% Latino) were randomized (30 bottle, 33 control). At baseline, 49% of participants had HIV RNA <20 copies/mL and 61% reported 100% adherence with antiretroviral medications over the prior 4 days. From baseline to week 12, median TFV-DP levels increased from 1230 to 1887 fmol/punch in the smart-bottle group compared to a decrease from 1108 to 1048 fmol/punch in controls (see figure; median change +252 versus -41 fmol/punch, respectively, p=0.101). Discontinuation rates were 5 of 30 (17%) in the smart-bottle group vs. 7 of 33 (22%) in the control group (p=0.89). The number of participants with HIV RNA >20 copies/mL at baseline who decreased to ≤20 copies/mL at 12 weeks was 3 of 24 in the smart-bottle group vs. 7 of 26 in the control group (OR for the intervention 0.4; 95% CI 0.1, 2.0). The median change in CD4 count from baseline to week 12 was +14 cells/µL in the smart-bottle group and -16 cells/µL in the control group (p=0.36). At week 12, 75% of the smart-bottle group and 77% of the control group reported 100% adherence taking their antiretroviral medications over the prior 4 days.

This pilot study demonstrates that in patients with HIV infection on ART, the smart-pill bottle service was associated with higher tenofovir diphosphate levels (though this did not reach statistical significance); HIV RNA suppression rates, CD4 cell counts, and self-reported adherence rates (over the prior 4 days) were not different.